[Multicenter evaluation of a new local antihistaminic drug (levocabastine)].
The aim of this prospective, open study was to evaluate the efficacy and tolerance of the Levocabastine eye drops in daily practice. 273 patients with allergic (rhino)conjunctivitis were treated during 2 weeks. Objective findings and subjective assessments made by the patients were analyzed. The global efficacy was evaluated by the investigator as good or excellent in 73.8% (eye) and 53.6% (nose) of the patients. The results were not age-dependent. The tolerance was scored as good or excellent in 89% of the patients. Less than 6% of the patients stopped the treatment due to intolerance.
Klinik für Augenkrankheiten, Kantonsspital St. Gallen.
P
P
Bischoff
M
M
Gerber
D000328:Adult; D003233:Conjunctivitis, Allergic / Q000188:drug therapy*; D005260:Female; D006634:Histamine H1 Antagonists / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D009883:Ophthalmic Solutions; D010880:Piperidines / Q000008:administration & dosage* / Q000009:adverse effects
D006634:Histamine H1 Antagonists; D009883:Ophthalmic Solutions; D010880:Piperidines; C047340:levocabastine
Multizentrische Prüfung eines neuen lokalen Antihistaminikums (Levocabastin).